Ephedraone composition with anti-hypoxia activity

By optimizing the extraction process of fern ephedrine and combining it with eel bone polypeptides, the problems of low extraction efficiency and low utilization rate of active ingredients in the development of natural drugs have been solved, realizing the efficient preparation and clinical application of hypoxia-resistant drugs.

CN121129952APending Publication Date: 2025-12-16QINGDAO AGRI UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511519030.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-23
Publication Date
2025-12-16

AI Technical Summary

Technical Problem

The current development of natural medicines suffers from problems such as extensive traditional processing methods, severe loss of active ingredients, low extraction efficiency, low utilization rate of functional components, insufficient added value of products, and low standardization. In particular, when preparing hypoxia-resistant drugs, chemically synthesized drugs have side effects, artificial oxygen carriers have metabolic burden and potential toxicity, and natural drugs have low bioavailability and single target of action.

Method used

Pteris ephedrine was extracted by high-speed shearing of ethanol solution followed by boiling and reflux. Combined with eel bone polypeptide, the process was optimized to improve the extraction rate and bioactivity, thus preparing a composition with hypoxia-resistant activity.

Benefits of technology

It significantly improved the hypoxia tolerance activity of the compound of fern ephedrine and eel bone polypeptide, enhanced the bioavailability and clinical efficacy of natural drugs, and provided an efficient development path for hypoxia tolerance-related products.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a fern ephedra ketone composition with anti-hypoxia activity, and a fern ephedra ketone extract is obtained by taking an ethanol solution as an extracting solution, performing high-speed shearing, performing boiling reflux extraction, centrifuging the extracting solution, taking supernatant, and performing vacuum concentration. The amino acid sequence of the polypeptide with the hypoxia tolerance activity is SEQ ID NO: 1-7. The composition prepared by compounding the fern ephedra ketone and the eel bone polypeptide has remarkable advantages in an anti-hypoxia activity test. The anti-hypoxia activity of the composition is obviously superior to the effect of singly using pteridin-ephedra ketone or eel bone polypeptide, so that the pteridin-ephedra ketone and the eel bone polypeptide have a remarkable synergistic interaction effect in a specific proportion. The beneficial effect not only improves the biological activity of the composition, but also provides a new technical path for developing efficient anti-hypoxia related products, and has significant application value and industrialization potential.
Need to check novelty before this filing date? Find Prior Art